SCHEMBL10200140

SCHEMBL10200140

COCCCNCCCCCCOc1ccc(C)cc1

nearest known ligand 0.74

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ DRD2 P14416 12/20 0.74
▸ DRD4 P21917 12/20 0.74
▸ DRD3 P35462 11/20 0.74
▸ KDM4E B2RXH2 4/20 0.57
▸ NPC1 O15118 2/20 0.57
▸ LMNA P02545 2/20 0.57
▸ MEN1 O00255 1/20 0.57
▸ KMT2A Q03164 1/20 0.57
▸ CYP1A2 P05177 1/20 0.53
▸ CYP2D6 P10635 1/20 0.53
▸ MAPK1 P28482 1/20 0.53
▸ CYP2C19 P33261 1/20 0.53
▸ TP53 P04637 1/20 0.50
▸ ALOX15 P16050 1/20 0.50
▸ ALDH1A1 P00352 1/20 0.50
▸ SMN1; SMN2 Q16637 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10200141 0.98 DRD2 (0.77) DRD2DRD4DRD3KDM4ENPC1
SCHEMBL14232115 0.88 DRD2 (0.57) DRD2DRD4DRD3KDM4ENPC1
SCHEMBL14926393 0.88 DRD2 (0.57) DRD2DRD4DRD3KDM4ENPC1
Hydrochloric Acid SCHEMBL8042240 0.86 DRD2 (0.92) DRD2DRD4DRD3KDM4ENPC1
SCHEMBL5987245 0.86 DRD2 (0.59) DRD2DRD4DRD3KDM4ENPC1
Hydrochloric Acid SCHEMBL8042265 0.84 DRD4 (0.96) DRD2DRD4DRD3KDM4E
SCHEMBL12835040 0.83 TP53 (0.71) DRD2DRD4DRD3KDM4ENPC1
SCHEMBL16358123 0.83 DRD2 (0.69) DRD2DRD4DRD3KDM4ENPC1
SCHEMBL12549929 0.82 DRD2 (0.52) DRD2DRD4DRD3NPC1CYP2D6
SCHEMBL15581256 0.82 DRD2 (0.52) DRD2DRD4DRD3NPC1CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8372860-B2 Carboline derivatives useful in the inhibition of angiogenesis PTC THERAPEUTICS, INC. (US) 2013-02-12 — — US disclosed
EP-2298304-A2 Carboline derivatives useful in the treatment of cancer PTC Therapeutics, Inc. (US) 2011-03-23 — — EP disclosed
US-20100179132-A1 CARBOLINE DERIVATIVES USEFUL IN THE INHIBITION OF ANGIOGENESIS PTC THERAPEUTICS, INC. 2010-07-15 — — US disclosed
US-20100158858-A1 ADMINISTRATION OF CARBOLINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISEASES PTC THERAPEUTICS, INC. 2010-06-24 — — US disclosed
US-7601840-B2 Carboline derivatives useful in the inhibition of angiogenesis PTC THERAPEUTICS, INC. (US) 2009-10-13 — — US disclosed
US-20070281962-A2 Administering 1,2,3,6-tetrasubstituted pyrido[3,4-b]indoles to inhibit the 5'-untranslated region-dependent translation; anticarcinogenic agents; retinopathy, rheumatoid arthritis, psoriasis, atherosclerosis, obesity, macular degeneration PCT THERAPEUTICS, INC. (US) 2007-12-06 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100158858-A1 ADMINISTRATION OF CARBOLINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISEASES RNMT, VEGFA, VHL DRD2 2555/4885DRD4 2703/4885DRD3 3519/4885
US-20070281962-A2 Administering 1,2,3,6-tetrasubstituted pyrido[3,4-b]indoles to inhibit the 5'-untranslated region-dependent translation; anticarcinogenic agents; retinopathy, rheumatoid arthritis, psoriasis, atherosclerosis, obesity, macular degeneration VEGFA, FLT4, MIF DRD2 1595/4885DRD4 505/4885DRD3 1507/4885
US-20100179132-A1 CARBOLINE DERIVATIVES USEFUL IN THE INHIBITION OF ANGIOGENESIS VEGFA, FLT4, PGF DRD2 1441/4885DRD4 900/4885DRD3 2662/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback